Next Article in Journal
Bombesins: A New Frontier in Hybrid Compound Development
Previous Article in Journal
Nerve Regeneration with a Scaffold Incorporating an Absorbable Zinc-2% Iron Alloy Filament to Improve Axonal Guidance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 11
10.3390/pharmaceutics15112596
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Retraction of Pharmaceutics 2023, 15(5), 1565.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565

by
Anna-Maria Wiesinger
1,2,*,
Brian Bigger
2,3,
Roberto Giugliani
4,
Christina Lampe
2,5,
Maurizio Scarpa
2,6,
Tobias Moser
7,
Christoph Kampmann
8,
Georg Zimmermann
9,10 and
Florian B. Lagler
1,2
1
Institute of Congenital Metabolic Diseases, Paracelsus Medical University, 5020 Salzburg, Austria
2
European Reference Network for Hereditary Metabolic Diseases, MetabERN, 33100 Udine, Italy
3
Stem Cell and Neurotherapies, Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK
4
Department of Genetics, Medical Genetics Service and Biodiscovery Laboratory, Portal Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Casa dos Raros, Porto Alegre 90610-261, Brazil
5
Department of Child Neurology, Epilepetology and Social Pediatrics, Center of Rare Diseases, University Hospital Giessen/Marburg, 35392 Giessen, Germany
6
Regional Coordinating Center for Rare Diseases, University Hospital Udine, 33100 Udine, Italy
7
Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, 5020 Salzburg, Austria
8
Department of Pediatric Cardiology, University Hospital Mainz, 55131 Mainz, Germany
9
Team Biostatistics and Big Medical Data, IDA Lab Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria
10
Research and Innovation Management, Paracelsus Medical University, 5020 Salzburg, Austria
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(11), 2596; https://doi.org/10.3390/pharmaceutics15112596
Submission received: 18 October 2023 / Accepted: 19 October 2023 / Published: 7 November 2023
(This article belongs to the Section Drug Delivery and Controlled Release)
Versions Notes
The journal retracts the article, An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis [1], cited above, with the mutual agreement and support of the authors.
Following publication, concerns were brought to the attention of the publisher regarding the use of unpublished trial data without appropriate permission and potential concerns about the accuracy of the data.
Adhering to our complaints procedure, an investigation was conducted that confirmed a lack of appropriate permission from the authors and the conference organizers (Worldsymposium) in using incomplete trial data of anakira in MPS III NCT04018755, incorrectly presenting a placebo in the trial, using a table of incorrect data in the supplementary information, as well as the preliminary nature of this data meaning they could not be yet fully be relied upon to support the main findings of this study, leading to errors in values and calculations. This article is therefore retracted.
This retraction was approved by the Editor-in-Chief of the journal Pharmaceutics.
The authors agree to this retraction.

Reference

  1. Wiesinger, A.-M.; Bigger, B.; Giugliani, R.; Lampe, C.; Scarpa, M.; Moser, T.; Kampmann, C.; Zimmermann, G.; Lagler, F.B. RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wiesinger, A.-M.; Bigger, B.; Giugliani, R.; Lampe, C.; Scarpa, M.; Moser, T.; Kampmann, C.; Zimmermann, G.; Lagler, F.B. RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565. Pharmaceutics 2023, 15, 2596. https://doi.org/10.3390/pharmaceutics15112596

AMA Style

Wiesinger A-M, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T, Kampmann C, Zimmermann G, Lagler FB. RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565. Pharmaceutics. 2023; 15(11):2596. https://doi.org/10.3390/pharmaceutics15112596

Chicago/Turabian Style

Wiesinger, Anna-Maria, Brian Bigger, Roberto Giugliani, Christina Lampe, Maurizio Scarpa, Tobias Moser, Christoph Kampmann, Georg Zimmermann, and Florian B. Lagler. 2023. "RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565" Pharmaceutics 15, no. 11: 2596. https://doi.org/10.3390/pharmaceutics15112596

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop